A randomized, double-blind, placebo-controlled study of tumor necrosis factor- blockade in severe persistent asthma


Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlen, S.-E., Holgate, S. T., Meyers, D. A., Rabe, K. F., Antczak, A., Baker, J., Horvath, I., Mark, Z., Bernstein, D., Kerwin, E., Schlenker-Herceg, R., Lo, K. H., Watt, R., Barnathan, E. S. and Chanez, P. (2009) A randomized, double-blind, placebo-controlled study of tumor necrosis factor- blockade in severe persistent asthma. American Journal of Respiratory and Critical Care Medicine, 179, (7), 549-558. (doi:10.1164/rccm.200809-1512OC).

Download

[img] PDF
Restricted to Repository staff only

Download (340Kb) | Request a copy

Description/Abstract

Rationale: The treatment effect of golimumab, a human monoclonal antibody against tumor necrosis factor (TNF)-?, in severe persistent asthma is unknown.

Objectives: To assess the safety and efficacy of golimumab in a large population of patients with uncontrolled, severe persistent asthma.

Methods: From 2004 to 2006, 309 patients with severe and uncontrolled asthma, despite high-dose inhaled corticosteroids and long-acting ?2 agonists, were randomized 1:1:1:1 to monthly subcutaneous injections of placebo or golimumab (50, 100, or 200 mg) through Week 52. Coprimary endpoints were the change from baseline through Week 24 in prebronchodilator percent-predicted FEV1 and the number of severe asthma exacerbations through Week 24.

Measurements and Main Results: No significant differences were observed for the change in percent-predicted FEV1 (least squares mean: placebo, 2.44 [95% confidence interval (CI) ?0.574 to 5.461]; combined 100-mg and 200-mg, 2.91 [0.696–5.116]) or severe exacerbations (mean ± SD: placebo, 0.5 ± 1.07 vs. combined 100-mg and 200-mg 0.5 ± 0.97) through week 24. Through Week 24, 2.6% of patients treated with placebo vs. 19.5% of those treated with golimumab discontinued the study agent, and 1.3% and 7.8% discontinued study participation, respectively. An unfavorable risk–benefit profile led to early discontinuation of study-agent administration after the Week-24 database lock. Through Week 76, 20.5% of patients treated with placebo and 30.3% of patients treated with golimumab experienced serious adverse events, with serious infections occurring more frequently in golimumab-treated patients. One death and all eight malignancies occurred in the active groups.

Conclusions: Overall, treatment with golimumab did not demonstrate a favorable risk–benefit profile in this study population of patients with severe persistent asthma.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1164/rccm.200809-1512OC
ISSNs: 1073-449X (print)
1535-4970 (electronic)
Related URLs:
Subjects: R Medicine > RC Internal medicine
Divisions : Faculty of Medicine > Clinical and Experimental Sciences
ePrint ID: 341520
Accepted Date and Publication Date:
Status
January 2009Published
Date Deposited: 26 Jul 2012 14:32
Last Modified: 31 Mar 2016 14:32
URI: http://eprints.soton.ac.uk/id/eprint/341520

Actions (login required)

View Item View Item

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics